Abstract:Objective: The aim of this study is to assess the postoperative efficacy of the combined administration of dienogest (DNG) and gonadotropin-releasing hormone agonists (GnRH-a) in patients diagnosed with endometriosis (EMS), while acknowledging the extensive use of DNG in the extended therapeutic management of EMS. Methods: In this retrospective study, a cohort of 154 patients who underwent conservative surgical intervention for EMS were scrutinized. The cohort was stratified into two distinct groups based on their prescribed pharmacological regimens. Group A, 70 patients received postoperative oral administration of DNG at a dosage of 2 mg/day, whereas Group B, 84 patients underwent treatment involving 3 to 4 injections of GnRH-a post-surgery, followed by DNG therapy. Parameters assessed included pelvic pain visual analog scale (VAS) scores, quality of life metrics (EHP-5), and the incidence of adverse reactions within both groups. Results: Both groups exhibited sustained low VAS scores following the prescribed treatments. The predominant occurrence of adverse bleeding patterns manifested predominantly within the initial 6 months of the treatment. Notably, Group B demonstrated a significantly diminished of experiencing frequent and irregular bleeding in comparison to the DNG group (20.0% vs. 8.3%, 12.9% vs. 3.6%, p < 0.05). The administration of GnRH-a did not exacerbate the impact on bone health. Subsequent to health promotion interventions, the incidence of weight gain in both groups declined to 7.1% during the 6-month follow-up ( p < 0.05). Group B exhibited a 100% satisfaction rate with the treatment, concomitant with a noteworthy reduction in EHP-5 scores ( p < 0.05). Patients with deep infiltrating endometriosis (DIE) nodules displayed marginally higher postoperative VAS scores than their non-DIE counterparts (0.89 ± 0.96 vs. 0.49 ± 0.78). However, with sustained medication use, pain scores within the DIE group exhibited a continual decrease, maintaining a low level of 0.29 ± 0.67 at 12 months and beyond. Conclusion: The short-term adjunctive use of GnRH-a prior to DNG treatment postoperatively in patients with EMS proves efficacious in mitigating early adverse bleeding, enhancing patient adherence, and improving overall quality of life. Notably, this therapeutic approach demonstrates favorable safety profiles and is equally effective in patients with DIE.

Expression of GnRH-R in ectopic endometrial tissue and investigate therapeutic effect of GnRHa on patients with EMS

Correlation of Polypeptide N-Acetylgalactosamine Transferases-3 And-6 to Different Stages of Endometriosis

Effects of Gonadotropin-Releasing Hormone Antagonists on the Expression of Vascular Endothelial Growth Factor and Its Receptors in a Rat Model of Ovarian Hyperstimulation Syndrome.

Expression of Estrogen Receptor, Progesterone Receptor and Leukemia Inhibitory Factor on Endometrium During Different Ovarian Stimulation Protocols in Mice

Pgpm_a_354957 377..392

DDDT_A_270519 3673..3682

Expression of aquaporins in eutopic and ectopic endometrium of patients with endometriosis

Upregulation of H-Tert and Ki-67 in Ectopic Endometrium is Associated with Recurrence of Endometriosis

Effect of gonadotropin-releasing hormone agonist therapy after laparoscopic conservative surgery with moderate to severe endometriosis

Prolonged Gonadotropin-Releasing Hormone Agonist Therapy Reduced Expression of Nitric Oxide Synthase in the Endometrium of Women with Endometriosis and Infertility

Effect of GnRH II and GnRH I on secretion of VEGF by eutopic and ectopic endometrial stromal cells of endometriosis patients

Identification of NFASC and CHL1 As Two Novel Hub Genes in Endometriosis Using Integrated Bioinformatic Analysis and Experimental Verification.

Expression of Midkine in Eutopic and Ectopic Dndometrium of Patients with Adenomyosis after GnRHa Therapy

Evaluation on the application of GnRHa in patients with endometriosis after conservative surgery

Dienogest in conjunction with GnRH-a for postoperative management of endometriosis

Transcriptome analysis of eutopic endometrium in adenomyosis after GnRH agonist treatment

Effect of Starting Time of Ovarian Stimulation on Outcomes of in Vitro Fertilization in Women with Endometriosis

Curative Effect of 1.88-Mg and 3.75-Mg Gonadotrophin-Releasing Hormone Agonist on Stage III-IV Endometriosis: Randomized Controlled Study.

Changes in tissue inflammation, angiogenesis and apoptosis in endometriosis, adenomyosis and uterine myoma after GnRH agonist therapy

Expression Profiling of Coding and Noncoding RNAs in the Endometrium of Patients with Endometriosis

Expression profiles of E/P receptors and fibrosis in GnRHa-treated and -untreated women with different uterine leiomyomas